山东哪里看强制性脊柱炎(山东儿童强直性脊柱炎寿命) (今日更新中)

The family of late singer Tom Petty is upset with President Donald Trump for using the hit song "I Won’t Back Down.”The song was played at the president’s re-election rally in Tulsa, Oklahoma, over the weekend.That in turn prompted the late star's estate to issue a cease and desist notice to Trump's campaign on Saturday.Adria, Annakim, Dana and Jane Petty wrote in a letter posted to Twitter that Trump was not authorized to use the song to “further a campaign that leaves too many Americans and common sense behind.”The estate said, "both the late Tom Petty and his family firmly stand against racism and discrimination of any kind."They added that "Tom Petty would never want a song of his used for a campaign of hate. He liked to bring people together."The letter also said, “We believe in America and we believe in democracy. But Donald Trump is not representing the noble ideals of either."The Trump campaign has yet to release a response about the use of the song. 980

The coronavirus is shaking up America’s liquor laws.At least 33 states and the District of Columbia are temporarily allowing cocktails to-go during the pandemic. Only two — Florida and Mississippi — allowed them on a limited basis before coronavirus struck, according to the Distilled Spirits Council of the United States.Struggling restaurants say it’s a lifeline, letting them rehire bartenders, pay rent and reestablish relationships with customers. But others want states to slow down, saying the decades-old laws help ensure public safety.Julia Momose closed Kumiko, her Japanese-style cocktail bar in Chicago, on March 16. The next day, Illinois allowed bars and restaurants to start selling unopened bottles of beer, wine and liquor, but mixed drinks were excluded.Momose spent the next three months collecting petition signatures and pressing lawmakers to allow carryout cocktails. It worked. On June 17, she poured her first to-go drink: a Seaflower, made with gin, vermouth, Japanese citrus fruit and fermented chili paste. A carryout bottle, which serves two, costs .Momose has been able to hire back four of her furloughed employees. A group she co-founded, Cocktails for Hope, is now helping restaurants buy glass bottles in bulk for carryout.“Part of getting cocktails to go approved was embracing the fact that this isn’t going to fix everything, but it is going to fix something,” Momose said. “All these little things that we do will keep us open and keep our staff employed.”U.S. liquor laws — many of which date to the end of Prohibition in 1933 —are a confusing jumble that vary by state, city and county.Carryout cocktail regulations — which were passed starting in March — only deepen that confusion. Lawmakers approved carryout cocktails in some states; governors approved them in others. Nevada passed no statewide measure, but individual cities like Las Vegas and Reno allow them. In Pennsylvania, only restaurants and bars that lost 25% of average monthly total sales can sell cocktails to go.Most carryout cocktail regulations require customers to buy food with their mixed drinks. Lids or seals are generally required, but some states say drinks also need to be transported in the trunk. Marbet Lewis, a founding partner at Spiritus Law in Miami who specializes in the alcohol industry, says IDs should be checked — online or in person — by restaurants and bars as well as by delivery drivers.Some states, like Arizona, allow third party delivery companies like DoorDash to deliver cocktails; Kansas only allows delivery within a 50-foot radius.The laws also have different sunset dates. Alabama is only allowing carryout cocktails through Sept. 15, while Colorado and Massachusetts have extended them into next year. Michigan is allowing them through 2025.Last month, Iowa became the first state to permanently allow carryout and delivery of cocktails. Lawmakers in Ohio and Oklahoma are considering a similar measure, and the governors of Texas and Florida have expressed support for the change.There is overwhelming public support for making cocktails to go permanent, says Mike Whatley, vice president of state and local affairs for the National Restaurant Association. Between 75% and 80% of respondents have said they support carryout cocktails in numerous state polls, Whatley said.U.S. restaurants and bars have lost an estimated 5 billion since March due to lockdowns and social distancing requirements, the association said. In a May survey of 3,800 restaurants, the association found that 78% of operators who were selling alcohol to go had brought back laid-off employees, compared to 62% of operators overall.But some are urging states not to be too hasty. Mothers Against Drunk Driving worries that permanent carryout cocktails will lead to an increase in drunken driving unless laws make clear that the drinks can’t be consumed until the buyer is in a safe location.The U.S. government hasn’t released preliminary drunk driving data for 2020. But Jonathan Adkins, the executive director of the Governors Highway Safety Association, said there’s no anecdotal evidence that drunk driving has spiked during the pandemic.Patrick Maroney, a former liquor control officer in Colorado who is now a consultant, said carryout beer and wine — which was allowed in around 15 states prior to the pandemic — are different from cocktails because the containers are sealed by the manufacturer and the alcohol content is lower. Cocktails are mixed at the bar, so the alcohol content can vary and they may not be properly sealed, he said.Maroney said states need to make sure police and health officials are consulted before changing laws that have worked for decades. He noted that California reported a spike in reports of alcohol delivery to minors in April.“Are law enforcement officials worried about an ‘open air’ type atmosphere?” he said. “Is the law restricted to at-home consumption? How do they enforce it?”Maroney received funding from the Center for Alcohol Policy — which is funded by beer wholesalers — for a recent research paper raising concerns about carryout cocktails.Even before the coronavirus hit, there was a push to modernize alcohol laws to reflect the growing popularity of food delivery, Lewis said. She thinks lawmakers will have a hard time reinstating bans on carryout cocktails once the pandemic eases.“Once you get the genie out of the bottle and there hasn’t been a problem, how do you get it back in?” she said.Still, restaurant and bar owners say they’re not worried that patrons will get so used to carryout that they’ll stop going out even after the coronavirus has passed.“I think that people are social. People enjoy the bar experience and like being waited on,” said Dave Kwiatkowski, who owns the Sugar House cocktail bar in Detroit, which closed March 15 but was able to reopen July 10 for carryout service.Kwiatkowski normally employs a staff of 16. For now, it’s just him at the door and a bartender making drinks.“It’s enough to pay the electricity and the insurance, and it’s nice to give at least a couple of people some jobs,” he said.Kwiatkowski does wonder how he’ll handle carryout demand once the pandemic has ended and there’s a crowd in the bar on a Saturday night. But that will be a good problem to have, he said. He wants carryout cocktails to be permanently legalized.“I think this is probably going to change how we do business forever,” he said. 6446

The federal government says the fund providing a 0 weekly unemployment insurance boost is running out, but all eligible unemployed workers will still get their share. The Federal Emergency Management Agency says the jobless boost will end up providing benefits for just six weeks. The program was created last month by President Donald Trump to replace a more generous 0-a-week supplement that had been authorized by Congress but expired. So far, billion of the billion set aside for the program has been sent to states and U.S. territories. 563

The deadliest shooting in Texas history could have claimed even more lives if it weren't for a local resident who confronted the gunman, and another man who helped chase down the shooter.The resident, whose name has not yet been released, ran out of his house barefoot and exchanged gunfire with the shooter before the gunman sped away in a pearl-colored Fort Explorer. The armed resident then hailed a man across the street and got in his truck, telling him to chase down the gunman."I had to catch the guy. I had to make sure he was caught and at that point the gentleman riding with me said you may have to use your truck to get him off the road and there was no hesitation. It was do everything necessary to make sure that this guy is stopped," the motorist, Johnnie Langendorff said.Hear everything Johnnie Langendorff had to say: At a news conference Sunday night, investigators offered a preliminary timeline of the attack at the First Baptist Church in Sutherland Springs and laid out the role the resident played. Langendorff spoke to CNN on Monday.The gunman entered the small church in the rural town east of San Antonio, firing with an assault weapon at the congregation attending the morning service.A local resident grabbed his own rifle and engaged the gunman, said Freeman Martin, the regional director of the Texas Department of Public Safety."The suspect dropped his rifle, which was a Ruger AR assault-type rifle and fled from the church," said Martin."What do you say to the man who stepped up when he heard the gunshots? I'd say he's a hero," Wilson County Sheriff Joe Tackitt Jr. told CNN's Chris Cuomo on Monday. "I don't think there's any question about that. Had he not done what he did, we could have lost more people."He was just driving byLangendorff said he was driving by the church on the way to his girlfriend's house when he saw gunfire between the shooter and the armed resident.Langendorff told CNN that both men had weapons drawn."There was exchange of gunfire. It lasted just a few seconds, and the shooter got in his vehicle and took off," he said.The armed resident opened Langendorff's door, said the gunman shot up the church and urged the driver to step on it."We got to chase him," the man said, according to Langendorff. He said he answered, "Let's go."They gave chase in his truck for 11 miles and called police dispatch to tell them where they were and in what direction they were headed. The chase was 10 to 12 minutes long."The vehicle was in sight and I was picking up, getting closer and closer to it. We hit about 95 (mph) ... trying to catch this guy until he eventually lost control on his own and went off into the ditch," Langendorff told CNN affiliate KSAT."The gentleman that was with me got out and rested his rifle on my hood and kept it aimed at him (the shooter), telling him to get out. There was no movement, there was none of that. I just know his brake lights were going on and off, so he might've been unconscious from the crash or something like that. I'm not sure."Langendorff felt the suspect, who crashed his vehicle near the county line, "just gave up."When police arrived about five minutes later, they approached the suspect's vehicle and found the gunman inside dead of a bullet wound. He was later identified as Devin Patrick Kelley.Asked by CNN what he was thinking at the time, Langendorff said, "Nothing. Get him." Why? "Because that's what you do, you chase a bad guy."The shooting was a horrific tragedy, Langendorff said, but he hopes the families of the victims can sleep better knowing the shooter "was taken care of."And he has no regrets about throwing himself into such a dangerous situation."I hope that everyone affected is able to rest a little better knowing that this guy, he'll never breathe again. It doesn't serve it justice completely. But he won't hurt anyone else ever."Bravery seen at another church shootingLangendorff praised the resident for his quick action and called him "very much a hero."He emerged barefooted, grabbing his gun before he grabbed his shoes."He did absolutely the right thing, which was try to take him down at the scene," he said.The shooting at the church claimed 26 lives.Investigators "are continuing in their efforts as they put all the pieces of a very complex puzzle together to try to provide their community all the answers they need and deserve," Texas Gov. Greg Abbott said.It's the deadliest mass shooting in Texas history -- and the fifth deadliest in modern US history.The Sutherland Springs resident's actions echoed another man's act of bravery during a different church shooting earlier this year in Antioch, Tennessee.As the service at the Burnette Chapel Church of Christ was ending on September 24, a gunman -- whom police identified as 25-year-old Emanuel Kidega Samson -- entered the church with a pair of pistols and started firing. An usher at the church, Robert Engle, sprang into action -- struggling with the suspect, even as he was being pistol-whipped, police said."Mr. Samson didn't expect Mr. Engle to encounter him, to struggle with him, to try to stop the shooting," said Don Aaron, the spokesman for the Metropolitan Nashville Police Department.During the altercation, the gunman accidentally shot himself in the chest with his own weapon, police said.When the gunman fell, Engle, despite his head injuries, ran to his car and came back with a pistol of his own, police said.Engle, who has a permit for a handgun, then made sure Samson stayed on the ground until officers arrived, Aaron said.  5564

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

来源：资阳报